Endocrine Society of Australia position statement on male hypogonadism (part 1): assessment and indications for testosterone therapy

Bu B. Yeap, Mathis Grossmann, Robert I. McLachlan, David J Handelsman, Gary A. Wittert, Ann J. Conway, Bronwyn Ga Stuckey, Douglas W. Lording, Carolyn A. Allan, Jeffrey D Zajac, Henry G. Burger

Research output: Contribution to journalArticleOtherpeer-review

Abstract

INTRODUCTION: This article, Part 1 of the Endocrine Society of Australia's position statement on male hypogonadism, focuses on assessment of male hypogonadism, including the indications for testosterone therapy. (Part 2 will deal with treatment and therapeutic considerations.)

MAIN RECOMMENDATIONS: Key points and recommendations are:Pathological hypogonadism arises due to diseases of the hypothalamus or pituitary gland (hypogonadotropic hypogonadism) or testes (hypergonadotropic hypogonadism). It is a clinical diagnosis with a pathological basis, confirmed by hormone assays.Hormonal assessment is based on measurement of circulating testosterone, luteinising hormone (LH) and follicle-stimulating hormone (FSH) concentrations. Measurement of sex hormone-binding globulin levels can be informative, but use of calculated free testosterone is not recommended for clinical decision making.Testosterone replacement therapy is warranted in men with pathological hypogonadism, regardless of age.Currently, there are limited data from high-quality randomised controlled trials with clinically meaningful outcomes to justify testosterone treatment in older men, usually with chronic disease, who have low circulating testosterone levels but without hypothalamic, pituitary or testicular disease.Obesity, metabolic syndrome and type 2 diabetes are associated with lowering of circulating testosterone level, but without elevation of LH and FSH levels. Whether these are non-specific consequences of non-reproductive disorders or a correctable deficiency state is unknown, but clear evidence for efficacy and safety of testosterone therapy in this setting is lacking.Glucocorticoid and opioid use is associated with possibly reversible reductions in circulating testosterone level, without elevation of LH and FSH levels. Where continuation of glucocorticoid or opioid therapy is necessary, review by an endocrinologist may be warranted.Changes in management as result of the position statement: Men with pathological hypogonadism should be identified and considered for testosterone therapy, while further research is needed to clarify whether there is a role for testosterone in these other settings.

Original languageEnglish
Pages (from-to)173-178
Number of pages6
JournalMedical Journal of Australia
Volume205
Issue number4
Publication statusPublished - 15 Aug 2016

Cite this

Yeap, Bu B. ; Grossmann, Mathis ; McLachlan, Robert I. ; Handelsman, David J ; Wittert, Gary A. ; Conway, Ann J. ; Stuckey, Bronwyn Ga ; Lording, Douglas W. ; Allan, Carolyn A. ; Zajac, Jeffrey D ; Burger, Henry G. / Endocrine Society of Australia position statement on male hypogonadism (part 1) : assessment and indications for testosterone therapy. In: Medical Journal of Australia. 2016 ; Vol. 205, No. 4. pp. 173-178.
@article{587aee6c18ed4fdfaeb610d6c32ebeef,
title = "Endocrine Society of Australia position statement on male hypogonadism (part 1): assessment and indications for testosterone therapy",
abstract = "INTRODUCTION: This article, Part 1 of the Endocrine Society of Australia's position statement on male hypogonadism, focuses on assessment of male hypogonadism, including the indications for testosterone therapy. (Part 2 will deal with treatment and therapeutic considerations.)MAIN RECOMMENDATIONS: Key points and recommendations are:Pathological hypogonadism arises due to diseases of the hypothalamus or pituitary gland (hypogonadotropic hypogonadism) or testes (hypergonadotropic hypogonadism). It is a clinical diagnosis with a pathological basis, confirmed by hormone assays.Hormonal assessment is based on measurement of circulating testosterone, luteinising hormone (LH) and follicle-stimulating hormone (FSH) concentrations. Measurement of sex hormone-binding globulin levels can be informative, but use of calculated free testosterone is not recommended for clinical decision making.Testosterone replacement therapy is warranted in men with pathological hypogonadism, regardless of age.Currently, there are limited data from high-quality randomised controlled trials with clinically meaningful outcomes to justify testosterone treatment in older men, usually with chronic disease, who have low circulating testosterone levels but without hypothalamic, pituitary or testicular disease.Obesity, metabolic syndrome and type 2 diabetes are associated with lowering of circulating testosterone level, but without elevation of LH and FSH levels. Whether these are non-specific consequences of non-reproductive disorders or a correctable deficiency state is unknown, but clear evidence for efficacy and safety of testosterone therapy in this setting is lacking.Glucocorticoid and opioid use is associated with possibly reversible reductions in circulating testosterone level, without elevation of LH and FSH levels. Where continuation of glucocorticoid or opioid therapy is necessary, review by an endocrinologist may be warranted.Changes in management as result of the position statement: Men with pathological hypogonadism should be identified and considered for testosterone therapy, while further research is needed to clarify whether there is a role for testosterone in these other settings.",
author = "Yeap, {Bu B.} and Mathis Grossmann and McLachlan, {Robert I.} and Handelsman, {David J} and Wittert, {Gary A.} and Conway, {Ann J.} and Stuckey, {Bronwyn Ga} and Lording, {Douglas W.} and Allan, {Carolyn A.} and Zajac, {Jeffrey D} and Burger, {Henry G.}",
year = "2016",
month = "8",
day = "15",
language = "English",
volume = "205",
pages = "173--178",
journal = "Medical Journal of Australia",
issn = "0025-729X",
publisher = "AMPCo",
number = "4",

}

Yeap, BB, Grossmann, M, McLachlan, RI, Handelsman, DJ, Wittert, GA, Conway, AJ, Stuckey, BG, Lording, DW, Allan, CA, Zajac, JD & Burger, HG 2016, 'Endocrine Society of Australia position statement on male hypogonadism (part 1): assessment and indications for testosterone therapy' Medical Journal of Australia, vol. 205, no. 4, pp. 173-178.

Endocrine Society of Australia position statement on male hypogonadism (part 1) : assessment and indications for testosterone therapy. / Yeap, Bu B.; Grossmann, Mathis; McLachlan, Robert I.; Handelsman, David J; Wittert, Gary A.; Conway, Ann J.; Stuckey, Bronwyn Ga; Lording, Douglas W.; Allan, Carolyn A.; Zajac, Jeffrey D; Burger, Henry G.

In: Medical Journal of Australia, Vol. 205, No. 4, 15.08.2016, p. 173-178.

Research output: Contribution to journalArticleOtherpeer-review

TY - JOUR

T1 - Endocrine Society of Australia position statement on male hypogonadism (part 1)

T2 - assessment and indications for testosterone therapy

AU - Yeap, Bu B.

AU - Grossmann, Mathis

AU - McLachlan, Robert I.

AU - Handelsman, David J

AU - Wittert, Gary A.

AU - Conway, Ann J.

AU - Stuckey, Bronwyn Ga

AU - Lording, Douglas W.

AU - Allan, Carolyn A.

AU - Zajac, Jeffrey D

AU - Burger, Henry G.

PY - 2016/8/15

Y1 - 2016/8/15

N2 - INTRODUCTION: This article, Part 1 of the Endocrine Society of Australia's position statement on male hypogonadism, focuses on assessment of male hypogonadism, including the indications for testosterone therapy. (Part 2 will deal with treatment and therapeutic considerations.)MAIN RECOMMENDATIONS: Key points and recommendations are:Pathological hypogonadism arises due to diseases of the hypothalamus or pituitary gland (hypogonadotropic hypogonadism) or testes (hypergonadotropic hypogonadism). It is a clinical diagnosis with a pathological basis, confirmed by hormone assays.Hormonal assessment is based on measurement of circulating testosterone, luteinising hormone (LH) and follicle-stimulating hormone (FSH) concentrations. Measurement of sex hormone-binding globulin levels can be informative, but use of calculated free testosterone is not recommended for clinical decision making.Testosterone replacement therapy is warranted in men with pathological hypogonadism, regardless of age.Currently, there are limited data from high-quality randomised controlled trials with clinically meaningful outcomes to justify testosterone treatment in older men, usually with chronic disease, who have low circulating testosterone levels but without hypothalamic, pituitary or testicular disease.Obesity, metabolic syndrome and type 2 diabetes are associated with lowering of circulating testosterone level, but without elevation of LH and FSH levels. Whether these are non-specific consequences of non-reproductive disorders or a correctable deficiency state is unknown, but clear evidence for efficacy and safety of testosterone therapy in this setting is lacking.Glucocorticoid and opioid use is associated with possibly reversible reductions in circulating testosterone level, without elevation of LH and FSH levels. Where continuation of glucocorticoid or opioid therapy is necessary, review by an endocrinologist may be warranted.Changes in management as result of the position statement: Men with pathological hypogonadism should be identified and considered for testosterone therapy, while further research is needed to clarify whether there is a role for testosterone in these other settings.

AB - INTRODUCTION: This article, Part 1 of the Endocrine Society of Australia's position statement on male hypogonadism, focuses on assessment of male hypogonadism, including the indications for testosterone therapy. (Part 2 will deal with treatment and therapeutic considerations.)MAIN RECOMMENDATIONS: Key points and recommendations are:Pathological hypogonadism arises due to diseases of the hypothalamus or pituitary gland (hypogonadotropic hypogonadism) or testes (hypergonadotropic hypogonadism). It is a clinical diagnosis with a pathological basis, confirmed by hormone assays.Hormonal assessment is based on measurement of circulating testosterone, luteinising hormone (LH) and follicle-stimulating hormone (FSH) concentrations. Measurement of sex hormone-binding globulin levels can be informative, but use of calculated free testosterone is not recommended for clinical decision making.Testosterone replacement therapy is warranted in men with pathological hypogonadism, regardless of age.Currently, there are limited data from high-quality randomised controlled trials with clinically meaningful outcomes to justify testosterone treatment in older men, usually with chronic disease, who have low circulating testosterone levels but without hypothalamic, pituitary or testicular disease.Obesity, metabolic syndrome and type 2 diabetes are associated with lowering of circulating testosterone level, but without elevation of LH and FSH levels. Whether these are non-specific consequences of non-reproductive disorders or a correctable deficiency state is unknown, but clear evidence for efficacy and safety of testosterone therapy in this setting is lacking.Glucocorticoid and opioid use is associated with possibly reversible reductions in circulating testosterone level, without elevation of LH and FSH levels. Where continuation of glucocorticoid or opioid therapy is necessary, review by an endocrinologist may be warranted.Changes in management as result of the position statement: Men with pathological hypogonadism should be identified and considered for testosterone therapy, while further research is needed to clarify whether there is a role for testosterone in these other settings.

UR - http://www.scopus.com/inward/record.url?scp=85016622527&partnerID=8YFLogxK

M3 - Article

VL - 205

SP - 173

EP - 178

JO - Medical Journal of Australia

JF - Medical Journal of Australia

SN - 0025-729X

IS - 4

ER -